Skip to main content
UniHealth

Doctor search

Richard O Chen, MD

Dermatology · Stanford

NPI 1598929069

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
11
3 carriers
Offices
3

Offices

3 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

11 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chen’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

11 of 11 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A105615 · Current

Licensed to practise in California · since 2008 · expires 2028-08-31 · Stanford University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$16,494

Medicare paid this office $16,494 for 118 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Short return visit (20+ min)69$4,953$56
Return visit (30+ min)42$3,682$75
Destruction of precancer skin growth, 1 growth50$3,018$45
Destruction of skin growth, 1-14 growths27$2,146$65
Short return visit18$680$30
See all 7 services
Every Original Medicare service billed
Short return visit (20+ min)69$4,953$56
Return visit (30+ min)42$3,682$75
Destruction of precancer skin growth, 1 growth50$3,018$45
Destruction of skin growth, 1-14 growths27$2,146$65
Short return visit18$680$30
Biopsy of related skin growth, first growth22$459$19
Destruction of precancer skin growth, 2-14 growths40$422$2

Procedures Medicare counted

Procedure volume Medicare published
Removal of skin lesions187More than 79% of doctors who do this
Skin biopsy36More than 67% of doctors who do this

Who their Medicare patients are

118 Original Medicare patients in 2024. Average age 74 · Women 53% · Also on Medicaid 16% · Health risk score 1.29. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.

Conditions among them: High blood pressure 56% · Diabetes 25% · Cancer 25% · Coronary heart disease 23% · Chronic kidney disease 20% · Atrial fibrillation 14% · Heart failure 11% · Depression 11%.

The office billed $71,388, Medicare allowed $22,830 and paid $16,494; for 557 services of 15 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024118557741.29$71,388$16,494
202395454741.11$51,897$14,098
202289420741.01$46,167$11,901
202189377761.11$37,690$10,234
202079272741.24$35,062$7,347
201981326731.36$26,526$8,104
201892366721.56$28,987$9,033
201780391730.98$31,094$8,958
201690385721.35$33,490$9,732
201590371721.18$34,017$8,843
201480440711.18$38,409$9,246
201375445701.14$35,743$9,800

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 7 services

Original Medicare services billed in 2023
Short return visit (20+ min)63$4,445$54
Destruction of precancer skin growth, 1 growth46$3,054$46
Return visit (30+ min)29$2,825$86
Destruction of skin growth, 1-14 growths24$1,695$63
Short return visit14$643$32
Biopsy of related skin growth, first growth19$442$21
Destruction of precancer skin growth, 2-14 growths41$331$2

2022: 6 services

Original Medicare services billed in 2022
Short return visit (20+ min)69$4,379$47
Return visit (30+ min)23$2,319$80
Destruction of precancer skin growth, 1 growth39$2,153$39
Destruction of skin growth, 1-14 growths17$1,346$64
Biopsy of related skin growth, first growth12$307$24
Destruction of precancer skin growth, 2-14 growths31$274$1

2021: 6 services

Original Medicare services billed in 2021
Short return visit (20+ min)79$5,233$53
Destruction of precancer skin growth, 1 growth43$2,220$45
Destruction of skin growth, 1-14 growths20$1,075$51
Biopsy of related skin growth, first growth18$454$25
Short return visit11$399$29
Destruction of precancer skin growth, 2-14 growths38$316$2

2020: 5 services

Original Medicare services billed in 2020
Short return visit (20+ min)54$2,713$39
Destruction of precancer skin growth, 1 growth31$1,850$49
Short return visit22$587$18
Biopsy of related skin growth, first growth14$310$19
Destruction of precancer skin growth, 2-14 growths24$146$2

2019: 5 services

Original Medicare services billed in 2019
Short return visit (20+ min)60$3,200$42
Destruction of precancer skin growth, 1 growth25$1,396$44
Short return visit14$457$22
Biopsy of related skin growth, first growth12$438$27
Destruction of precancer skin growth, 2-14 growths22$218$2

2018: 6 services

Original Medicare services billed in 2018
Short return visit (20+ min)65$3,484$38
Destruction of precancer skin growth, 1 growth33$1,888$40
New patient visit (30+ min)14$849$61
Biopsy of single growth of skin and/or tissue21$642$29
Short return visit21$607$20
Destruction of precancer skin growth, 2-14 growths24$198$2

2017: 6 services

Original Medicare services billed in 2017
Short return visit (20+ min)59$3,421$41
Destruction of precancer skin growth, 1 growth34$1,986$43
Destruction of skin growth, 1-14 growths12$887$49
Short return visit20$633$20
Biopsy of single growth of skin and/or tissue13$400$31
Destruction of precancer skin growth, 2-14 growths28$333$2

2016: 5 services

Original Medicare services billed in 2016
Short return visit (20+ min)71$4,030$42
Destruction of precancer skin growth, 1 growth43$2,667$46
Short return visit28$775$20
Biopsy of single growth of skin and/or tissue12$421$35
Destruction of precancer skin growth, 2-14 growths32$275$2

2015: 5 services

Original Medicare services billed in 2015
Short return visit (20+ min)70$4,024$42
Destruction of precancer skin growth, 1 growth35$1,864$41
Biopsy of single growth of skin and/or tissue16$581$34
Short return visit21$373$16
Destruction of precancer skin growth, 2-14 growths25$272$2

2014: 7 services

Original Medicare services billed in 2014
Short return visit (20+ min)52$2,687$40
Destruction of precancer skin growth, 1 growth38$2,315$41
Return visit (30+ min)16$1,185$56
New patient visit (30+ min)16$946$59
Destruction of precancer skin growth, 2-14 growths33$460$2
Biopsy of single growth of skin and/or tissue12$421$35
Short return visit16$401$22

2013: 6 services

Original Medicare services billed in 2013
Short return visit (20+ min)53$3,515$39
Destruction of precancer skin growth, 1 growth24$1,957$47
Destruction of precancer skin growth, 2-14 growths20$826$4
Biopsy of single growth of skin and/or tissue21$655$28
New patient visit (30+ min)11$597$54
Short return visit18$474$19

Drugs they prescribed that Part D paid

$289,519

Pharmacies billed $289,519 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 246) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.

213 generic and 33 brand-name prescriptions · $289,519 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Taltz13$86,033$6,618
Desonide32$2,863$89
Fluocinonide13$796$61
Ketoconazole49$639$13
Metronidazole12$552$46
See all 7 drugs
Every Part D drug this clinician prescribed
Taltz13$86,033$6,618
Desonide32$2,863$89
Fluocinonide13$796$61
Ketoconazole49$639$13
Metronidazole12$552$46
Triamcinolone Acetonide40$501$13
Clobetasol Propionate12$473$39

Year by year

Part D prescribing by year
2024246780% (0)13%$289,519
2023265630% (0)12%$230,067
2022228520% (0)11%$176,225
2021157530% (0)None$40,323
2020137460% (0)None$22,176
2019134510% (0)13%$43,558
2018123370% (0)23%$57,446
2017123380% (0)25%$48,499
201618056None14%$49,538
2015257590% (0)11%$25,475
2014217490% (0)15%$18,320
2013146380% (0)18%$9,373

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 8 drugs

Part D drugs prescribed in 2023
Taltz13$92,476$7,114
Desonide18$2,007$111
Fluocinonide30$1,906$64
Clobetasol Propionate17$1,034$61
Fluorouracil11$844$77
Ketoconazole42$745$18
Triamcinolone Acetonide40$447$11
Minoxidil12$130$11

2022: 6 drugs

Part D drugs prescribed in 2022
Taltz13$88,073$6,775
Fluocinonide40$2,832$71
Ketoconazole52$900$17
Clobetasol Propionate13$837$64
Triamcinolone Acetonide27$438$16
Hydrocortisone13$213$16

2021: 4 drugs

Part D drugs prescribed in 2021
Fluocinonide21$1,024$49
Ketoconazole28$611$22
Triamcinolone Acetonide22$398$18
Ciclopirox12$314$26

2020: 5 drugs

Part D drugs prescribed in 2020
Ketoconazole29$730$25
Methotrexate13$641$49
Fluocinonide12$547$46
Clobetasol Propionate11$489$44
Triamcinolone Acetonide23$327$14

2019: 3 drugs

Part D drugs prescribed in 2019
Fluocinonide20$1,129$56
Ketoconazole32$554$17
Triamcinolone Acetonide20$397$20

2018: 2 drugs

Part D drugs prescribed in 2018
Ketoconazole30$516$17
Triamcinolone Acetonide15$298$20

2017: 3 drugs

Part D drugs prescribed in 2017
Fluocinonide21$1,752$83
Ketoconazole24$546$23
Triamcinolone Acetonide15$290$19

2016: 5 drugs

Part D drugs prescribed in 2016
Clobetasol Propionate27$6,718$249
Fluocinonide35$3,677$105
Doxycycline Hyclate11$3,202$291
Ketoconazole22$318$14
Triamcinolone Acetonide13$287$22

2015: 7 drugs

Part D drugs prescribed in 2015
Fluocinonide60$7,241$121
Clobetasol Propionate19$5,161$272
Desonide17$1,714$101
Methotrexate15$686$46
Hydroxyzine17$658$39
Triamcinolone Acetonide25$411$16
Ketoconazole16$213$13

2014: 4 drugs

Part D drugs prescribed in 2014
Clobetasol Propionate33$4,871$148
Fluocinonide44$2,750$62
Desonide20$2,222$111
Ketoconazole23$394$17

2013: 6 drugs

Part D drugs prescribed in 2013
Clobetasol Propionate23$1,461$64
Methotrexate12$1,078$90
Fluocinonide16$974$61
Hydroxyzine11$318$29
Ketoconazole12$313$26
Prednisone12$112$9

Money from drug and device companies

$31 in 2023

Industry payments by year
202312None$31
202011None$225

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
PfizerCibinqo$31
2 payments
  • Education for Cibinqo · 2023-05-10 · $15
  • Education for Cibinqo · 2023-04-12 · $15
See all 2 published payments
Every published payment
PfizerEducation · 2023-05-10Cibinqo$15
PfizerEducation · 2023-04-12Cibinqo$15
See earlier years (2020)

2020: $225

Payments by company in 2020
E.R. Squibb & Sons L.L.C.None$225
1 payment
  • Meals · 2020-01-14 · $225

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1598929069
Licence
CA A105615California A105615: Current · expires 2028-08-31
Trained
Stanford University School of Medicine, 2007
Gender
Male
More record details
Sole proprietor
Yes
Taxonomy
Federal specialty code 207N00000X (207N00000X)
Mailing address
450 Broadway Ave, Dept of Dermatology, Pavillion C, 2nd Floor, Redwood City, CA, 94063
NPI first listed
2008-07-15
NPI last updated
2024-04-16
NPI record certified
2024-04-16

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 450 Broadway Ave, Redwood City, CA, 94063